
Eleva commences Phase I clinical trial for C3G treatment
Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, aimed at treating C3-glomerulopathy (C3G), a rare renal disease. The trial is currently evaluating CPV-104’s single-ascending doses in healthy …